Bevacizumab vs. Triamcinolone

Ophthalmology

Volumn 117, Issue 4, 2010, Pages

  Soheilian, Masoud ^a   Rabbanikhah, Zahra ^a   Ramezani, Alireza ^a   Kiavash, Victoria ^a   Yaseri, Mehdi ^a   Peyman, Gholam A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

BEHCET DISEASE; CATARACT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTERMEDIATE UVEITIS; LETTER; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 77949595413     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.10.012     Document Type: Letter

References (5)

1. Antcliff R.J., Spalton D.J., Stanford M.R., et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108 (2001) 765-772
2. Cordero Coma M., Sobrin L., Onal S., et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114 (2007) 1574-1579
3. Mackensen F., Heinz C., Becker M.D., and Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28 (2008) 41-45
4. Stefánsson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 51 (2006) 364-380
5. Tong J.P., Lam D.S., Chan W.M., et al. Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol Vis 12 (2006) 1490-1495